Serpinc1 iRNA compositions and methods of use thereof

US9127274B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Akin Akinc · Cambridge, US
• Alfica Sehgal · Cambridge, US
• Ivanka Toudjarska · Medford, US
• Donald C. Foster · Lake Forest Park, US
• Stuart Milstein · Cambridge, US
• Brian Bettencourt · Groton, US
• Martin Maier · Cambridge, US
• Klaus Charisse · Acton, US
• Satyanarayana Kuchimanchi · Cambridge, US
• Kallanthottathil G. Rajeev · Wayland, US
• Muthiah Monaharan · Cambridge, US

Key dates

• Filing date: Mar 15, 2013
• Grant date: Sep 8, 2015
• Expiry date: Mar 22, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.